Analysts at StockNews.com started coverage on shares of Pieris Pharmaceuticals (NASDAQ:PIRS – Get Free Report) in a research report issued to clients and investors on Wednesday. The brokerage set a “hold” rating on the biotechnology company’s stock.
Pieris Pharmaceuticals Stock Down 15.7 %
Shares of NASDAQ:PIRS opened at $13.60 on Wednesday. The business’s 50 day moving average is $16.09 and its 200 day moving average is $14.71. The stock has a market cap of $17.95 million, a P/E ratio of -1.12 and a beta of 0.61. Pieris Pharmaceuticals has a 52-week low of $6.20 and a 52-week high of $22.32.
Hedge Funds Weigh In On Pieris Pharmaceuticals
An institutional investor recently bought a new position in Pieris Pharmaceuticals stock. Frazier Life Sciences Management L.P. bought a new position in Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS – Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 15,942 shares of the biotechnology company’s stock, valued at approximately $267,000. Frazier Life Sciences Management L.P. owned approximately 1.21% of Pieris Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). 40.11% of the stock is currently owned by institutional investors.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.
Featured Articles
- Five stocks we like better than Pieris Pharmaceuticals
- Stock Market Upgrades: What Are They?
- 5 Reasons DraftKings Stock Looks Promising in the New Year
- Insider Buying Explained: What Investors Need to Know
- Cybersecurity Stocks: 1 Immediate Buy and 1 Dip Opportunity
- How to Calculate Stock Profit
- The Next 2 AI Winners Have Triple-Digit Upside Potential
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
